Testing effectiveness (Phase 2)Looking for participantsNCT05700721
What this trial is testing
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Who this might be right for
Brain Metastases
M.D. Anderson Cancer Center 120